Moberg Pharma acquires U.S OTC brand Balmex®

STOCKHOLM, April 27, 2015. Moberg Pharma AB (OMX: MOB) has acquired Balmex®, a
well-established Over-The-Counter brand in the U.S. from Chattem, Inc, the U.S.
Consumer Healthcare Division of Sanofi. Net sales of the brand is trending on an
annual rate exceeding $4 million. The purchase price is $3.9 million and
financed by available cash resources.
Balmex® is an established and trusted brand among parents with products used for
diaper rash, primarily in babies. An adult line for soothing skin irritations
was launched in 2013. The brand will be sold through Moberg’s current OTC
channel in the U.S, primarily in chain drugstores, such as CVS, Walgreens and
Rite Aid and in mass retailers, such as Walmart as well as specialty retailers
including Toys R’ Us and buybuyBABY.

“Adding Balmex to Moberg’s U.S. portfolio is a great fit, within our core area
of topical dermatology. We are continuously evaluating deal opportunities to
further leverage our U.S. sales and marketing infrastructure. This deal
contributes immediately to our sales and earnings and to our long term financial
goal of delivering profitable growth and an EBITDA margin of 25% from 2016”,
said Peter Wolpert, CEO of Moberg Pharma AB.

“We see excellent opportunities to build on the brand equity of Balmex and
utilize our Innovation Engine to further strengthen the future value proposition
of the brand to consumers and retailers”, said Jeff Vernimb, GM of Moberg Pharma
North America.

The transaction was completed April 24th, 2015.

About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 8.00 a.m. (CET) on April 27, 2015.
For additional information contact:
Peter Wolpert, CEO, Phone: +46 (0)70 - 735 7135, E-mail:
peter.wolpert@mobergpharma.se
Anna Ljung, CFO, Phone: +46 (0)70 - 766 60 30, E-mail:
anna.ljung@mobergpharma.se
Jeff Vernimb, GM Moberg Pharma North America, Phone: +1 (908) 420 9492, E-mail:
jvernimb@mobergpharma.com
About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
OTC sales operations in the U.S. and a distributor network in more than 40
countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal
Nail®, Balmex®, Jointflex®, Domeboro®, Vanquish®, and Fergon®. Kerasal
Nail®(Emtrix®or Nalox™ in certain ex-U.S. markets) is a leading OTC treatment of
nail disorders in the U.S., Canada and several EU markets and is currently being
launched in Southeast Asia. The company is growing organically as well as
through acquisitions. Internal development programs focuses on innovative drug
delivery of proven compounds and include two phase II assets, MOB-015
(onychomycosis) and BUPI (oral mucositis). Moberg Pharma has offices in
Stockholm and New Jersey and the company’s shares are listed on the Small Cap
list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB). For further
information, please visit: www.mobergpharma.com.